Biomea Fusion (BMEA) Stock Overview

A clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. More details

BMEA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 15% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

+ 2 more risks

BMEA Community Fair Values

Create Narrative

See what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Biomea Fusion, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Biomea Fusion
Historical stock prices
Current Share Price	US$1.43
52 Week High	US$3.08
52 Week Low	US$0.87
Beta	-0.34
1 Month Change	-26.67%
3 Month Change	14.40%
1 Year Change	0%
3 Year Change	-95.55%
5 Year Change	-91.83%
Change since IPO	-92.31%

Recent updates

Seeking Alpha • Oct 07

Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines

Summary Biomea Fusion shares spiked on positive 52-week Phase II data for icovamenib in type 2 diabetes, then fell after a $25M fundraising announcement. BMEA's icovamenib showed durable HbA1c reductions in severe insulin-deficient and GLP-1 non-responder subgroups, but broader efficacy remains unproven in larger populations. Despite a strengthened cash position extending into late 2026, significant risks persist, including funding needs for further trials and competition from established GLP-1 therapies. Given the high risk, uncertain broad efficacy, and dilution, I remain on the sidelines, though BMEA could appeal to speculative investors seeking potential outsized returns. Read the full article on Seeking Alpha

Analysis Article • Aug 17

Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analysis Article • Sep 30

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analysis Article • Jun 10

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analysis Article • Feb 22

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analysis Article • Nov 07

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysis Article • Jul 12

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analysis Article • Mar 29

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

	BMEA	US Biotechs	US Market
7D	-12.3%	1.0%	1.1%
1Y	0%	40.3%	26.7%

Return vs Industry: BMEA underperformed the US Biotechs industry which returned 44.4% over the past year.

Return vs Market: BMEA underperformed the US Market which returned 25.4% over the past year.

Price Volatility

Is BMEA's price volatile compared to industry and market?
BMEA volatility
BMEA Average Weekly Movement	14.3%
Biotechs Industry Average Movement	10.7%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: BMEA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: BMEA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2017	41	Mick Hitchcock	biomeafusion.com

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity.

Biomea Fusion, Inc. Fundamentals Summary

How do Biomea Fusion's earnings and revenue compare to its market cap?
BMEA fundamental statistics
Market cap	US$107.00m
Earnings (TTM)	-US$44.95m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-2.3x

P/E Ratio

Is BMEA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BMEA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$44.95m
Earnings	-US$44.95m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.62
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did BMEA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/14 11:29
End of Day Share Price	2026/05/14 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biomea Fusion, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Naureen Quibria	Capital One Securities, Inc.
Yigal Nochomovitz	Citigroup Inc
Jonathan Wolleben	Citizens JMP Securities, LLC

Biomea Fusion (BMEA) Stock Overview

Risk Analysis

Biomea Fusion, Inc. Competitors

Kalaris Therapeutics

Cardiff Oncology

Cue Biopharma

Cibus

Price History & Performance

Recent News & Updates

New minor risk - Market cap size

Biomea Fusion, Inc. Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea Fusion, Inc., Annual General Meeting, Jun 10, 2026

Biomea Fusion, Inc. Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

New major risk - Financial position

Biomea Fusion Presents Phase II Covalent-111 Data In Type 2 Diabetes At 19th International Conference On Advanced Technologies And Treatments For Diabetes

Recent updates

New minor risk - Market cap size

Biomea Fusion, Inc. Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea Fusion, Inc., Annual General Meeting, Jun 10, 2026

Biomea Fusion, Inc. Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

New major risk - Financial position

Biomea Fusion Presents Phase II Covalent-111 Data In Type 2 Diabetes At 19th International Conference On Advanced Technologies And Treatments For Diabetes

Biomea Fusion, Inc. Presents Covid-111 Study Results At the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

Co-Founder recently bought US$55k worth of stock

Biomea Fusion, Inc. Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide At Obesityweek®? 2025

Price target decreased by 10% to US$7.17

Biomea Fusion, Inc. Announces Impairment Charges for the Three Months Ended September 30, 2025

Biomea Fusion, Inc. Announces First Patient Dosed in Phase I Study of BMF-650 A Next-Generation Oral GLP-1 Receptor Agonist

Biomea Fusion Announces Positive 52-Week Results from Phase II Covid-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines

Biomea Fusion, Inc. has filed a Follow-on Equity Offering.

Biomea Fusion, Inc. Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model

Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?

Price target decreased by 27% to US$8.29

Biomea Fusion, Inc. Announces Board Changes

Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from Russell 2000 Index

Biomea Fusion, Inc. Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

New major risk - Shareholder dilution

Biomea Fusion, Inc. has filed a Follow-on Equity Offering.

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent Flt3 Inhibitor Bf-500 in Relapsed or Refractory Acute Leukemia At Eha 2025

New major risk - Share price stability

Price target decreased by 14% to US$20.00

Biomea Fusion, Inc. Selects for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

Price target decreased by 13% to US$20.50

Biomea Fusion, Inc., Annual General Meeting, Jun 11, 2025

Biomea Fusion, Inc. Auditor Raises 'Going Concern' Doubt

Biomea Fusion, Inc. Announces Chief Executive Officer Changes

Biomea Fusion Inc. Announces Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-Cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Price target decreased by 34% to US$28.11

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Biomea Fusion, Inc. Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Biomea Fusion, Inc. Presents the New Analysis from the Escalation Portion of COVALENT-111 at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

High number of new and inexperienced directors

Independent Director recently bought US$101k worth of stock

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc. Announces FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

New major risk - Financial position

High number of new and inexperienced directors

CFO & Principal Accounting Officer recently bought US$55k worth of stock

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target decreased by 17% to US$41.00

Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold

New major risk - Share price stability

Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Price target increased by 10% to US$54.43

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)

Price target decreased by 9.2% to US$49.38

Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes

Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

New minor risk - Share price stability